for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Medknow Publishers   (Total: 429 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 429 Journals sorted alphabetically
Acta Medica Intl.     Open Access   (SJR: 0.101, CiteScore: 0)
Advanced Arab Academy of Audio-Vestibulogy J.     Open Access  
Advanced Biomedical Research     Open Access  
Advances in Human Biology     Open Access   (Followers: 3)
Advances in Skeletal Muscle Function Assessment     Open Access  
African J. for Infertility and Assisted Conception     Open Access  
African J. of Medical and Health Sciences     Open Access   (Followers: 2)
African J. of Paediatric Surgery     Open Access   (Followers: 7, SJR: 0.25, CiteScore: 1)
African J. of Trauma     Open Access   (Followers: 1)
Ain-Shams J. of Anaesthesiology     Open Access   (Followers: 3)
Al-Azhar Assiut Medical J.     Open Access  
Al-Basar Intl. J. of Ophthalmology     Open Access   (Followers: 1)
Alexandria J. of Pediatrics     Open Access  
Ancient Science of Life     Open Access   (Followers: 5)
Anesthesia : Essays and Researches     Open Access   (Followers: 10)
Annals of African Medicine     Open Access   (Followers: 1, SJR: 0.258, CiteScore: 1)
Annals of Bioanthropology     Open Access   (Followers: 4)
Annals of Cardiac Anaesthesia     Open Access   (Followers: 14, SJR: 0.308, CiteScore: 1)
Annals of Indian Academy of Neurology     Open Access   (Followers: 3, SJR: 0.434, CiteScore: 1)
Annals of Indian Academy of Otorhinolaryngology Head and Neck Surgery     Open Access  
Annals of Indian Psychiatry     Open Access  
Annals of Maxillofacial Surgery     Open Access   (Followers: 6)
Annals of Medical and Health Sciences Research     Open Access   (Followers: 7)
Annals of Nigerian Medicine     Open Access   (Followers: 1)
Annals of Pediatric Cardiology     Open Access   (Followers: 8, SJR: 0.352, CiteScore: 1)
Annals of Saudi Medicine     Open Access   (SJR: 0.238, CiteScore: 1)
Annals of Thoracic Medicine     Open Access   (Followers: 6, SJR: 0.524, CiteScore: 1)
Annals of Tropical Medicine and Public Health     Open Access   (Followers: 13, SJR: 0.152, CiteScore: 0)
Annals of Tropical Pathology     Open Access  
Apollo Medicine     Open Access  
APOS Trends in Orthodontics     Open Access  
Arab J. of Interventional Radiology     Open Access  
Archives of Cardiovascular Imaging     Open Access   (Followers: 1, SJR: 0.187, CiteScore: 0)
Archives of Intl. Surgery     Open Access   (Followers: 10, SJR: 0.302, CiteScore: 1)
Archives of Medicine and Health Sciences     Open Access   (Followers: 3)
Archives of Medicine and Surgery     Open Access  
Archives of Pharmacy Practice     Open Access   (Followers: 6, SJR: 0.102, CiteScore: 0)
Archives of Trauma Research     Open Access   (Followers: 3, SJR: 0.37, CiteScore: 2)
Asia Pacific J. of Clinical Trials : Nervous System Diseases     Open Access  
Asia-Pacific J. of Oncology Nursing     Open Access   (Followers: 4)
Asian J. of Andrology     Open Access   (Followers: 1, SJR: 0.856, CiteScore: 2)
Asian J. of Neurosurgery     Open Access   (Followers: 2)
Asian J. of Oncology     Open Access   (Followers: 1)
Asian J. of Transfusion Science     Open Access   (Followers: 1, SJR: 0.35, CiteScore: 1)
Asian Pacific J. of Reproduction     Open Access   (SJR: 0.227, CiteScore: 1)
Asian Pacific J. of Tropical Biomedicine     Open Access   (Followers: 2, SJR: 0.491, CiteScore: 2)
Asian Pacific J. of Tropical Medicine     Open Access   (Followers: 1, SJR: 0.561, CiteScore: 2)
Astrocyte     Open Access  
Avicenna J. of Medicine     Open Access   (Followers: 1)
AYU : An international quarterly journal of research in Ayurveda     Open Access   (Followers: 6)
Benha Medical J.     Open Access  
Biomedical and Biotechnology Research J.     Open Access  
BLDE University J. of Health Sciences     Open Access  
Brain Circulation     Open Access  
Bulletin of Faculty of Physical Therapy     Open Access   (Followers: 1)
Canadian J. of Rural Medicine     Full-text available via subscription   (SJR: 0.202, CiteScore: 0)
Cancer Translational Medicine     Open Access   (Followers: 2)
Cardiology Plus     Open Access  
Chinese Medical J.     Open Access   (Followers: 10, SJR: 0.52, CiteScore: 1)
CHRISMED J. of Health and Research     Open Access  
Clinical Cancer Investigation J.     Open Access  
Clinical Dermatology Review     Open Access   (Followers: 2)
Clinical Trials in Degenerative Diseases     Open Access  
Clinical Trials in Orthopedic Disorders     Open Access  
Community Acquired Infection     Open Access  
Conservation and Society     Open Access   (Followers: 10, SJR: 0.811, CiteScore: 2)
Contemporary Clinical Dentistry     Open Access   (Followers: 4, SJR: 0.353, CiteScore: 1)
Current Medical Issues     Open Access   (Followers: 1)
CytoJ.     Open Access   (Followers: 2, SJR: 0.543, CiteScore: 1)
Delta J. of Ophthalmology     Open Access  
Dental Hypotheses     Open Access   (Followers: 3, SJR: 0.152, CiteScore: 0)
Dental Research J.     Open Access   (Followers: 11, SJR: 0.416, CiteScore: 1)
Dentistry and Medical Research     Open Access  
Digital Medicine     Open Access  
Drug Development and Therapeutics     Open Access  
Education for Health     Open Access   (Followers: 6, SJR: 0.242, CiteScore: 0)
Egyptian J. of Bronchology     Open Access  
Egyptian J. of Cardiothoracic Anesthesia     Open Access  
Egyptian J. of Cataract and Refractive Surgery     Open Access   (Followers: 1, SJR: 1.799, CiteScore: 2)
Egyptian J. of Chest Diseases and Tuberculosis     Open Access   (Followers: 3, SJR: 0.155, CiteScore: 0)
Egyptian J. of Dermatology and Venerology     Open Access   (Followers: 1)
Egyptian J. of Haematology     Open Access   (Followers: 1)
Egyptian J. of Internal Medicine     Open Access   (Followers: 1)
Egyptian J. of Neurology, Psychiatry and Neurosurgery     Open Access   (Followers: 1, SJR: 0.127, CiteScore: 0)
Egyptian J. of Obesity, Diabetes and Endocrinology     Open Access   (Followers: 1)
Egyptian J. of Otolaryngology     Open Access   (Followers: 2)
Egyptian J. of Psychiatry     Open Access   (Followers: 2)
Egyptian J. of Surgery     Open Access   (Followers: 1)
Egyptian Nursing J.     Open Access  
Egyptian Orthopaedic J.     Open Access   (Followers: 2)
Egyptian Pharmaceutical J.     Open Access  
Egyptian Retina J.     Open Access  
Egyptian Rheumatology and Rehabilitation     Open Access  
Endodontology     Open Access  
Endoscopic Ultrasound     Open Access   (SJR: 0.822, CiteScore: 2)
Environmental Disease     Open Access   (Followers: 3)
Eurasian J. of Pulmonology     Open Access  
European J. of Dentistry     Open Access   (Followers: 2, SJR: 0.749, CiteScore: 2)
European J. of General Dentistry     Open Access   (Followers: 1, SJR: 0.12, CiteScore: 0)
European J. of Prosthodontics     Open Access   (Followers: 3)
European J. of Psychology and Educational Studies     Open Access   (Followers: 11, SJR: 0.113, CiteScore: 0)
Fertility Science and Research     Open Access  
Formosan J. of Surgery     Open Access   (SJR: 0.112, CiteScore: 0)
Genome Integrity     Open Access   (Followers: 3, SJR: 0.153, CiteScore: 0)
Glioma     Open Access  
Global J. of Transfusion Medicine     Open Access   (Followers: 1)
Gynecology and Minimally Invasive Therapy     Open Access   (SJR: 0.311, CiteScore: 1)
Hamdan Medical J.     Open Access  
Heart and Mind     Open Access  
Heart India     Open Access   (Followers: 1)
Heart Views     Open Access   (Followers: 2)
Hepatitis B Annual     Open Access   (Followers: 3)
Ibnosina J. of Medicine and Biomedical Sciences     Open Access  
IJS Short Reports     Open Access  
Imam J. of Applied Sciences     Open Access  
Indian Anaesthetists Forum     Open Access  
Indian Dermatology Online J.     Open Access   (Followers: 3)
Indian J. of Allergy, Asthma and Immunology     Open Access   (Followers: 1)
Indian J. of Anaesthesia     Open Access   (Followers: 7, SJR: 0.478, CiteScore: 1)
Indian J. of Burns     Open Access   (Followers: 1)
Indian J. of Cancer     Open Access   (Followers: 1, SJR: 0.361, CiteScore: 1)
Indian J. of Cerebral Palsy     Open Access   (Followers: 1)
Indian J. of Community Medicine     Open Access   (Followers: 2, SJR: 0.37, CiteScore: 1)
Indian J. of Critical Care Medicine     Open Access   (Followers: 3, SJR: 0.604, CiteScore: 1)
Indian J. of Dental Research     Open Access   (Followers: 4, SJR: 0.266, CiteScore: 1)
Indian J. of Dental Sciences     Open Access  
Indian J. of Dentistry     Open Access   (Followers: 1)
Indian J. of Dermatology     Open Access   (Followers: 2, SJR: 0.468, CiteScore: 1)
Indian J. of Dermatology, Venereology and Leprology     Open Access   (Followers: 5, SJR: 0.445, CiteScore: 1)
Indian J. of Dermatopathology and Diagnostic Dermatology     Open Access  
Indian J. of Drugs in Dermatology     Open Access   (Followers: 1, SJR: 0.791, CiteScore: 1)
Indian J. of Endocrinology and Metabolism     Open Access   (Followers: 4, SJR: 0.568, CiteScore: 1)
Indian J. of Health Sciences     Open Access   (Followers: 2)
Indian J. of Medical and Paediatric Oncology     Open Access   (SJR: 0.425, CiteScore: 1)
Indian J. of Medical Microbiology     Open Access   (Followers: 1, SJR: 0.503, CiteScore: 1)
Indian J. of Medical Research     Open Access   (Followers: 4, SJR: 0.656, CiteScore: 1)
Indian J. of Medical Sciences     Open Access   (Followers: 2, SJR: 0.102, CiteScore: 0)
Indian J. of Multidisciplinary Dentistry     Open Access   (Followers: 1)
Indian J. of Nephrology     Open Access   (Followers: 2, SJR: 0.347, CiteScore: 1)
Indian J. of Nuclear Medicine     Open Access   (Followers: 2, SJR: 0.23, CiteScore: 0)
Indian J. of Occupational and Environmental Medicine     Open Access   (Followers: 3, SJR: 0.225, CiteScore: 1)
Indian J. of Ophthalmology     Open Access   (Followers: 4, SJR: 0.498, CiteScore: 1)
Indian J. of Oral Health and Research     Open Access  
Indian J. of Oral Sciences     Open Access   (Followers: 1)
Indian J. of Orthopaedics     Open Access   (Followers: 8, SJR: 0.392, CiteScore: 1)
Indian J. of Otology     Open Access   (Followers: 1, SJR: 0.199, CiteScore: 0)
Indian J. of Paediatric Dermatology     Open Access   (Followers: 2)
Indian J. of Pain     Open Access   (Followers: 1)
Indian J. of Palliative Care     Open Access   (Followers: 5, SJR: 0.454, CiteScore: 1)
Indian J. of Pathology and Microbiology     Open Access   (Followers: 2, SJR: 0.276, CiteScore: 1)
Indian J. of Pharmacology     Open Access   (SJR: 0.412, CiteScore: 1)
Indian J. of Plastic Surgery     Open Access   (Followers: 12, SJR: 0.311, CiteScore: 0)
Indian J. of Psychiatry     Open Access   (Followers: 3, SJR: 0.408, CiteScore: 1)
Indian J. of Psychological Medicine     Open Access   (SJR: 0.368, CiteScore: 1)
Indian J. of Public Health     Open Access   (Followers: 1)
Indian J. of Radiology and Imaging     Open Access   (Followers: 4)
Indian J. of Research in Homoeopathy     Open Access  
Indian J. of Respiratory Care     Open Access  
Indian J. of Rheumatology     Open Access   (SJR: 0.119, CiteScore: 0)
Indian J. of Sexually Transmitted Diseases and AIDS     Open Access   (Followers: 2, SJR: 0.34, CiteScore: 0)
Indian J. of Social Psychiatry     Open Access   (Followers: 2)
Indian J. of Transplantation     Open Access  
Indian J. of Urology     Open Access   (Followers: 3, SJR: 0.434, CiteScore: 1)
Indian J. of Vascular and Endovascular Surgery     Open Access   (Followers: 2)
Indian Spine J.     Open Access  
Industrial Psychiatry J.     Open Access   (Followers: 2)
Intervention     Open Access   (Followers: 1)
Intl. Archives of Health Sciences     Open Access  
Intl. J. of Abdominal Wall and Hernia Surgery     Open Access   (Followers: 1)
Intl. J. of Academic Medicine     Open Access  
Intl. J. of Advanced Medical and Health Research     Open Access  
Intl. J. of Applied and Basic Medical Research     Open Access  
Intl. J. of Clinical and Experimental Physiology     Open Access   (Followers: 1)
Intl. J. of Clinicopathological Correlation     Open Access  
Intl. J. of Community Dentistry     Open Access  
Intl. J. of Critical Illness and Injury Science     Open Access   (Followers: 1, SJR: 0.192, CiteScore: 0)
Intl. J. of Educational and Psychological Researches     Open Access   (Followers: 4)
Intl. J. of Environmental Health Engineering     Open Access   (Followers: 1)
Intl. J. of Forensic Odontology     Open Access   (Followers: 1)
Intl. J. of Green Pharmacy     Open Access   (Followers: 3, SJR: 0.142, CiteScore: 0)
Intl. J. of Growth Factors and Stem Cells in Dentistry     Open Access  
Intl. J. of Health & Allied Sciences     Open Access   (Followers: 3)
Intl. J. of Health System and Disaster Management     Open Access   (Followers: 3)
Intl. J. of Heart Rhythm     Open Access  
Intl. J. of Medicine and Public Health     Open Access   (Followers: 6)
Intl. J. of Mycobacteriology     Open Access   (SJR: 0.535, CiteScore: 1)
Intl. J. of Noncommunicable Diseases     Open Access  
Intl. J. of Nutrition, Pharmacology, Neurological Diseases     Open Access   (Followers: 4, SJR: 0.17, CiteScore: 0)
Intl. J. of Oral Health Sciences     Open Access   (Followers: 2)
Intl. J. of Orofacial Biology     Open Access   (Followers: 1)
Intl. J. of Orofacial Research     Open Access   (Followers: 1)
Intl. J. of Orthodontic Rehabilitation     Open Access  
Intl. J. of Pedodontic Rehabilitation     Open Access  
Intl. J. of Pharmaceutical Investigation     Open Access   (Followers: 1)
Intl. J. of Preventive Medicine     Open Access   (Followers: 1, SJR: 0.623, CiteScore: 1)
Intl. J. of Shoulder Surgery     Open Access   (Followers: 5, SJR: 0.653, CiteScore: 1)
Intl. J. of the Cardiovascular Academy     Open Access   (SJR: 0.105, CiteScore: 0)
Intl. J. of Trichology     Open Access   (SJR: 0.4, CiteScore: 1)
Intl. J. of Yoga     Open Access   (Followers: 14)
Intl. J. of Yoga : Philosophy, Psychology and Parapsychology     Open Access   (Followers: 5)

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Journal Cover
Asian Journal of Andrology
Journal Prestige (SJR): 0.856
Citation Impact (citeScore): 2
Number of Followers: 1  

  This is an Open Access Journal Open Access journal
ISSN (Print) 1008-682X - ISSN (Online) 1745-7262
Published by Medknow Publishers Homepage  [429 journals]
  • The path forward in prostate cancer therapeutics

    • Authors: Jeanny B Aragon-Ching, Ravi A Madan
      Pages: 213 - 214
      Abstract: Jeanny B Aragon-Ching, Ravi A Madan
      Asian Journal of Andrology 2018 20(3):213-214

      Citation: Asian Journal of Andrology 2018 20(3):213-214
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_3_18
      Issue No: Vol. 20, No. 3 (2018)
       
  • Bone-targeted therapies to reduce skeletal morbidity in prostate cancer

    • Authors: Tanya B Dorff, Neeraj Agarwal
      Pages: 215 - 220
      Abstract: Tanya B Dorff, Neeraj Agarwal
      Asian Journal of Andrology 2018 20(3):215-220
      Bone metastases are the main driver of morbidity and mortality in advanced prostate cancer. Targeting the bone microenvironment, a key player in the pathogenesis of bone metastasis, has become one of the mainstays of therapy in men with advanced prostate cancer. This review will evaluate the data supporting the use of bone-targeted therapy, including (1) bisphosphonates such as zoledronic acid, which directly target osteoclasts, (2) denosumab, a receptor activator of nuclear factor-kappa B (RANK) ligand inhibitor, which targets a key component of bone stromal interaction, and (3) radium-223, an alpha-emitting calcium mimetic, which hones to the metabolically active areas of osteoblastic metastasis and induces double-strand breaks in the DNA. Denosumab has shown enhanced delay in skeletal-related events compared to zoledronic acid in patients with metastatic castration-resistant prostate cancer (mCRPC). Data are mixed with regard to pain control as a primary measure of efficacy. New data call into question dosing frequency, with quarterly dosing strategy potentially achieving similar effect compared to monthly dosing for zoledronic acid. In the case of radium-223, there are data for both pain palliation and improved overall survival in mCRPC. Further studies are needed to optimize timing and combination strategies for bone-targeted therapies. Ongoing studies will explore the impact of combining bone-targeted therapy with investigational therapeutic agents such as immunotherapy, for advanced prostate cancer. Future studies should strive to develop biomarkers of response, in order to improve efficacy and cost-effectiveness of these agents.
      Citation: Asian Journal of Andrology 2018 20(3):215-220
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_12_18
      Issue No: Vol. 20, No. 3 (2018)
       
  • Role of chemotherapy in prostate cancer

    • Authors: Rita Nader, Joelle El Amm, Jeanny B Aragon-Ching
      Pages: 221 - 229
      Abstract: Rita Nader, Joelle El Amm, Jeanny B Aragon-Ching
      Asian Journal of Andrology 2018 20(3):221-229
      Chemotherapy in prostate cancer (PCa) has undergone dramatic landscape changes. While earlier studies utilized varying chemotherapy regimens which were found to be largely palliative in nature and hardly resulted in durable or meaningful responses, docetaxel resulted in the first chemotherapy agent that showed improvement in overall survival in metastatic castration-resistant prostate cancer (mCRPC). However, combination chemotherapy or any agents added to docetaxel have failed to yield incremental benefits. The improvement in overall survival as well as secondary endpoints of prostate-specific antigen (PSA) and time to recurrence when using docetaxel in the metastatic hormone-sensitive state has changed the standard of care for treatment of newly diagnosed de novo metastatic PCa. There are also promising results in locally advanced PCa and high-risk PCa in both the neoadjuvant and adjuvant settings. This review summarizes the historical as well as the more contemporary use of chemotherapeutic agents in PCa in varying states and phases of disease.
      Citation: Asian Journal of Andrology 2018 20(3):221-229
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_40_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Utility of cell-free nucleic acid and circulating tumor cell analyses in
           prostate cancer

    • Authors: Theodore Gourdin, Guru Sonpavde
      Pages: 230 - 237
      Abstract: Theodore Gourdin, Guru Sonpavde
      Asian Journal of Andrology 2018 20(3):230-237
      Prostate cancer is characterized by bone metastases and difficulty of objectively measuring disease burden. In this context, cell-free circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) quantitation and genomic profiling afford the ability to noninvasively and serially monitor the tumor. Recent data suggest that ctDNA and CTC quantitation are prognostic for survival. Indeed, CTC enumeration using the CellSearch® platform is validated as a prognostic factor and warrants consideration as a stratification factor in randomized trials. Changes in quantities of CTCs using CellSearch also are prognostic and may be employed to detect a signal of activity of new agents. Molecular profiling of both CTCs and ctDNA for androgen receptor (AR) variants has been associated with outcomes in the setting of novel androgen inhibitors. Serial profiling to detect the evolution of new alterations may inform drug development and help develop precision medicine. The costs of these assays and the small quantities in which they are detectable in blood are a limitation, and novel platforms are required to address this challenge. The presence of multiple platforms to assay CTCs and ctDNA also warrants the consideration of a mechanism to allow comparison of data across platforms. Further validation and the continued development and standardization of these promising modalities will facilitate their adoption in the clinic.
      Citation: Asian Journal of Andrology 2018 20(3):230-237
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_1_18
      Issue No: Vol. 20, No. 3 (2018)
       
  • The role of peroxisome proliferator-activated receptor gamma in prostate
           cancer

    • Authors: Catherine Elix, Sumanta K Pal, Jeremy O Jones
      Pages: 238 - 243
      Abstract: Catherine Elix, Sumanta K Pal, Jeremy O Jones
      Asian Journal of Andrology 2018 20(3):238-243
      Despite great progress in the detection and treatment of prostate cancer, this disease remains an incredible health and economic burden. Although androgen receptor (AR) signaling plays a key role in the development and progression of prostate cancer, aberrations in other molecular pathways also contribute to the disease, making it essential to identify and develop drugs against novel targets, both for the prevention and treatment of prostate cancer. One promising target is the peroxisome proliferator-activated receptor gamma (PPARγ) protein. PPARγ was originally thought to act as a tumor suppressor in prostate cells because agonist ligands inhibited the growth of prostate cancer cells; however, additional studies found that PPARγ agonists inhibit cell growth independent of PPARγ. Furthermore, PPARγ expression increases with cancer grade/stage, which would suggest that it is not a tumor suppressor but instead that PPARγ activity may play a role in prostate cancer development and/or progression. Indeed, two new studies, taking vastly different, unbiased approaches, have identified PPARγ as a target in prostate cancer and suggest that PPARγ inhibition might be useful in prostate cancer prevention and treatment. These findings could lead to a new therapeutic weapon in the fight against prostate cancer.
      Citation: Asian Journal of Andrology 2018 20(3):238-243
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_15_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Vitamin D in prostate cancer

    • Authors: Donald L Trump, Jeanny B Aragon-Ching
      Pages: 244 - 252
      Abstract: Donald L Trump, Jeanny B Aragon-Ching
      Asian Journal of Andrology 2018 20(3):244-252
      Signaling through the vitamin D receptor has been shown to be biologically active and important in a number of preclinical studies in prostate and other cancers. Epidemiologic data also indicate that vitamin D signaling may be important in the cause and prognosis of prostate and other cancers. These data indicate that perturbation of vitamin D signaling may be a target for the prevention and treatment of prostate cancer. Large studies of vitamin D supplementation will be required to determine whether these observations can be translated into prevention strategies. This paper reviews the available data in the use of vitamin D compounds in the treatment of prostate cancer. Clinical data are limited which support the use of vitamin D compounds in the management of men with prostate cancer. However, clinical trials guided by existing preclinical data are limited.
      Citation: Asian Journal of Andrology 2018 20(3):244-252
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_14_18
      Issue No: Vol. 20, No. 3 (2018)
       
  • Perspectives on the clinical development of immunotherapy in prostate
           cancer

    • Authors: Lisa M Cordes, James L Gulley, Ravi A Madan
      Pages: 253 - 259
      Abstract: Lisa M Cordes, James L Gulley, Ravi A Madan
      Asian Journal of Andrology 2018 20(3):253-259
      Despite impressive survival benefits with immunotherapy in patients with various solid tumors, the full potential of these agents in prostate cancer has yet to be realized. Sipuleucel-T demonstrated a survival benefit in this population, indicating that prostate cancer is an immunoresponsive disease; however, these results have not been matched by other agents. A large trial with ipilimumab in prostate cancer failed to meet its primary objective, and small trials with PD-1/PD-L1 inhibitors did not yield a significant improvement in overall response. However, several late-stage clinical trials are underway with other vaccines in prostate cancer. Reports of clinical benefit with immunotherapies, particularly when used in combination or a select population, have provided the framework to develop sound clinical trials. Understanding immunogenic modulation, antigen spread, biomarkers, and DNA-repair defects will also help mold future strategies. Through rational patient selection and evidence-based combination approaches, patients with prostate cancer may soon derive durable survival benefits with immunotherapies.
      Citation: Asian Journal of Andrology 2018 20(3):253-259
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_9_18
      Issue No: Vol. 20, No. 3 (2018)
       
  • Altered PIWI-LIKE 1 and PIWI-LIKE 2 mRNA expression in ejaculated
           spermatozoa of men with impaired sperm characteristics

    • Authors: Maria Giebler, Thomas Greither, Lisa Müller, Carina Mösinger, Hermann M Behre
      Pages: 260 - 264
      Abstract: Maria Giebler, Thomas Greither, Lisa Müller, Carina Mösinger, Hermann M Behre
      Asian Journal of Andrology 2018 20(3):260-264
      In about half the cases of involuntary childlessness, a male infertility factor is involved. The PIWI-LIKE genes, a subclade of the Argonaute protein family, are involved in RNA silencing and transposon control in the germline. Knockout of murine Piwi-like 1 and 2 homologs results in complete infertility in males. The aim of this study was to analyze whether the mRNA expression of human PIWI-LIKE 1–4 genes is altered in ejaculated spermatozoa of men with impaired sperm characteristics. Ninety male participants were included in the study, among which 47 were with normozoospermia, 36 with impaired semen characteristics according to the World Health Organization (WHO) manual, 5th edition, and 7 with azoospermia serving as negative control for the PIWI-LIKE 1–4 mRNA expression in somatic cells in the ejaculate. PIWI-LIKE 1–4 mRNA expression in the ejaculated spermatozoa of the participants was measured by quantitative real-time PCR. In nonazoospermic men, PIWI-LIKE 1–4 mRNA was measurable in ejaculated spermatozoa in different proportions. PIWI-LIKE 1 (100.0%) and PIWI-LIKE 2 (49.4%) were more frequently expressed than PIWI-LIKE 3 (9.6%) and PIWI-LIKE 4 (15.7%). Furthermore, a decreased PIWI-LIKE 2 mRNA expression showed a significant correlation with a decreased sperm count (P = 0.022) and an increased PIWI-LIKE 1 mRNA expression with a decreased progressive motility (P = 0.048). PIWI-LIKE 1 and PIWI-LIKE 2 mRNA expression exhibited a significant association with impaired sperm characteristics and may be a useful candidate for the evaluation of the impact of PIWI-LIKE 1–4 mRNA expression on male infertility.
      Citation: Asian Journal of Andrology 2018 20(3):260-264
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_58_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Histological subtype is a significant predictor for inguinal lymph node
           metastasis in patients with penile squamous cell carcinoma

    • Authors: Jin-You Wang, Ming-Zhu Gao, De-Xin Yu, Dong-Dong Xie, Yi Wang, Liang-Kuan Bi, Tao Zhang, De-Mao Ding
      Pages: 265 - 269
      Abstract: Jin-You Wang, Ming-Zhu Gao, De-Xin Yu, Dong-Dong Xie, Yi Wang, Liang-Kuan Bi, Tao Zhang, De-Mao Ding
      Asian Journal of Andrology 2018 20(3):265-269
      The present study aimed to investigate the relationship between histopathological subtype and the probability of inguinal lymph node metastasis (ILNM) in patients with penile squamous cell carcinoma (PSCC). The clinical records of 198 consecutive patients with PSCC were analyzed retrospectively. Primary lesions were reevaluated according to the 2016 World Health Organization (WHO) histopathological classification. We retrieved the clinicopathological factors from the medical records including age, clinical lymph node stage, pathological tumor stage, lymphatic invasion, and nerve invasion. Uni- and multivariate logistic regression analyses were used to explore the risk factors of ILNM. Multivariate analyses identified clinical lymph node stage (P = 0.000), pathological tumor stage (P = 0.016), histologic grade (P = 0.000), and risk group of histological subtypes (P = 0.029) as independent predictors for ILNM. Compared with the low-risk group of PSCC subtypes, the intermediate- (HR: 3.66, 95% CI: 1.30–10.37, P = 0.021) and high-risk groups (HR: 28.74, 95% CI: 2.37–348.54, P = 0.008) were significantly associated with ILNM. In conclusion, the histopathological subtype of the primary lesion is a significant predictor for ILNM in patients with PSCC.
      Citation: Asian Journal of Andrology 2018 20(3):265-269
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_60_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Intermittent, low-dose, antiandrogen monotherapy as an alternative
           therapeutic option for patients with positive surgical margins after
           radical prostatectomy

    • Authors: Kyung Hwa Choi, Seung Ryeol Lee, Young Kwon Hong, Dong Soo Park
      Pages: 270 - 275
      Abstract: Kyung Hwa Choi, Seung Ryeol Lee, Young Kwon Hong, Dong Soo Park
      Asian Journal of Andrology 2018 20(3):270-275
      The aim of the present study was to determine whether oncologic outcomes and adverse events associated with active on/off intermittent antiandrogen monotherapy (daily bicalutamide, 50 mg per day) are comparable with those of standard external beam radiation therapy (EBRT) or combined androgen blockade (CAB) therapy in prostate cancers with positive surgical margins after radical prostatectomy. Two hundred twenty-three patients with positive surgical margins post-radical prostatectomy who underwent active surveillance (AS, n = 32), EBRT without hormone therapy (n = 55), intermittent antiandrogen monotherapy without EBRT (IAAM, n = 50), or CAB without EBRT (n = 86), between 2007 and 2014, were reviewed retrospectively. Pathologic outcomes, biochemical recurrence rates, radiological disease progression, and adverse events were collected from medical records. Biochemical recurrence rates, biochemical recurrence-free survival rates, and radiological recurrence were not different between the groups (P = 0.225, 0.896, and 0.284, respectively). Adverse event rates and severities were lower for IAAM compared with EBRT or CAB (both P < 0.05), but were comparable to those for AS (P = 0.591 and 0.990, respectively). Grade ≥3 adverse events were not reported in the IAAM or AS groups. Erectile dysfunction and loss of libido rates were lower in the IAAM group compared with the EBRT and CAB groups (P = 0.032). Gastrointestinal complications were more frequently reported in the EBRT group (P = 0.008). Active on/off IAAM treatment might be an appropriate treatment option for patients with positive surgical margins after radical prostatectomy. Furthermore, regarding oncologic outcomes, IAAM was comparable to standard EBRT but had a milder adverse event profile.
      Citation: Asian Journal of Andrology 2018 20(3):270-275
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_56_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Androgen receptor deficiency in monocytes/macrophages does not alter
           adiposity or glucose homeostasis in male mice

    • Authors: Katya B Rubinow, Barbara Houston, Shari Wang, Leela Goodspeed, Kayoko Ogimoto, Gregory J Morton, Christopher McCarty, Robert E Braun, Stephanie T Page
      Pages: 276 - 283
      Abstract: Katya B Rubinow, Barbara Houston, Shari Wang, Leela Goodspeed, Kayoko Ogimoto, Gregory J Morton, Christopher McCarty, Robert E Braun, Stephanie T Page
      Asian Journal of Andrology 2018 20(3):276-283
      Androgen deprivation in men leads to increased adiposity, but the mechanisms underlying androgen regulation of fat mass have not been fully defined. Androgen receptor (AR) is expressed in monocytes/macrophages, which are resident in key metabolic tissues and influence energy metabolism in surrounding cells. Male mice bearing a cell-specific knockout of the AR in monocytes/macrophages (M-ARKO) were generated to determine whether selective loss of androgen signaling in these cells would lead to altered body composition. Wild-type (WT) and M-ARKO mice (12–22 weeks of age, n = 12 per group) were maintained on a regular chow diet for 8 weeks and then switched to a high-fat diet for 8 additional weeks. At baseline and on both the regular chow and high-fat diets, no differences in lean mass or fat mass were observed between groups. Consistent with the absence of differential body weight or adiposity, no differences in food intake (3.0 ± 0.5 g per day for WT mice vs 2.8 ± 0.4 g per day for M-ARKO mice) or total energy expenditure (0.6 ± 0.1 Kcal h−1 for WT mice vs 0.5 ± 0.1 Kcal h−1 for M-ARKO mice) were evident between groups during high-fat feeding. Liver weight was greater in M-ARKO than that in WT mice (1.5 ± 0.1 g vs 1.3 ± 0.0 g, respectively, P = 0.02). Finally, M-ARKO mice did not exhibit impairments in glucose tolerance or insulin sensitivity relative to WT mice at any study time point. In aggregate, these findings suggest that AR signaling specifically in monocytes/macrophages does not contribute to the regulation of systemic energy balance, adiposity, or insulin sensitivity in male mice.
      Citation: Asian Journal of Andrology 2018 20(3):276-283
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_54_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Transcription and regulation of hepatitis B virus genes in host sperm
           cells

    • Authors: Ying Zhong, Dong-Ling Liu, Mohamed Morsi M Ahmed, Peng-Hao Li, Xiao-Ling Zhou, Qing-Dong Xie, Xiao-Qing Xu, Ting-Ting Han, Zhi-Wei Hou, Ji-Hua Huang, Lan Xu, Tian-Hua Huang
      Pages: 284 - 289
      Abstract: Ying Zhong, Dong-Ling Liu, Mohamed Morsi M Ahmed, Peng-Hao Li, Xiao-Ling Zhou, Qing-Dong Xie, Xiao-Qing Xu, Ting-Ting Han, Zhi-Wei Hou, Ji-Hua Huang, Lan Xu, Tian-Hua Huang
      Asian Journal of Andrology 2018 20(3):284-289
      To investigate whether transcription of hepatitis B virus (HBV) gene occurs in human sperm, total RNA was extracted from sperm of patients with chronic HBV infection (test-1), from donor sperm transfected with a plasmid containing the full-length HBV genome (test-2), and from nontransfected donor sperm (control), used as the template for reverse transcription-polymerase chain reaction (RT-PCR). Positive bands for HBV DNA were observed in the test groups but not in the control. Next, to identify the role of host genes in regulating viral gene transcription in sperm, total RNA was extracted from 2-cell embryos derived from hamster oocytes fertilized in vitro by HBV-transfected (test) or nontransfected (control) human sperm and successively subjected to SMART-PCR, suppression subtractive hybridization, T/A cloning, bacterial amplification, microarray hybridization, sequencing and the Basic Local Alignment Search Tool (BLAST) search to isolate differentially expressed genes. Twenty-nine sequences showing significant identity to five human gene families were identified, with chorionic somatomammotropin hormone 2 (CSH2), eukaryotic translation initiation factor 4 gamma 2 (EIF4G2), pterin-4 alpha-carbinolamine dehydratase 2 (PCBD2), pregnancy-specific beta-1-glycoprotein 4 (PSG4) and titin (TTN) selected to represent target genes. Using real-time quantitative RT-PCR (qRT-PCR), when CSH2 and PCBD2 (or EIF4G2, PSG4 and TTN) were silenced by RNA interference, transcriptional levels of HBV s and x genes significantly decreased (or increased) (P < 0.05). Silencing of a control gene in sperm did not significantly change transcription of HBV s and x genes (P> 0.05). This study provides the first experimental evidence that transcription of HBV genes occurs in human sperm and is regulated by host genes.
      Citation: Asian Journal of Andrology 2018 20(3):284-289
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_46_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Proton-pump inhibitor use does not affect semen quality in subfertile men

    • Authors: Sorena Keihani, James R Craig, Chong Zhang, Angela P Presson, Jeremy B Myers, William O Brant, Kenneth I Aston, Benjamin R Emery, Timothy G Jenkins, Douglas T Carrell, James M Hotaling
      Pages: 290 - 293
      Abstract: Sorena Keihani, James R Craig, Chong Zhang, Angela P Presson, Jeremy B Myers, William O Brant, Kenneth I Aston, Benjamin R Emery, Timothy G Jenkins, Douglas T Carrell, James M Hotaling
      Asian Journal of Andrology 2018 20(3):290-293
      Proton-pump inhibitors (PPIs) are among the most widely used drugs worldwide. PPI use has recently been linked to adverse changes in semen quality in healthy men; however, the effects of PPI use on semen parameters remain largely unknown specifically in cases with male factor infertility. We examined whether PPI use was associated with detrimental effects on semen parameters in a large population of subfertile men. We retrospectively reviewed data from 12 257 subfertile men who had visited our fertility clinic from 2003 to 2013. Patients who reported using any PPIs for >3 months before semen sample collection were included; 7698 subfertile men taking no medication served as controls. Data were gathered on patient age, medication use, and conventional semen parameters; patients taking any known spermatotoxic medication were excluded. Linear mixed-effect regression models were used to test the effect of PPI use on semen parameters adjusting for age. A total of 248 patients (258 samples) used PPIs for at least 3 months before semen collection. In regression models, PPI use (either as the only medication or when used in combination with other nonspermatotoxic medications) was not associated with statistically significant changes in semen parameters. To our knowledge, this is the largest study to compare PPI use with semen parameters in subfertile men. Using PPIs was not associated with detrimental effects on semen quality in this retrospective study.
      Citation: Asian Journal of Andrology 2018 20(3):290-293
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_35_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • The transcription factor ZEB1 promotes an aggressive phenotype in prostate
           cancer cell lines

    • Authors: Octavio Orellana-Serradell, Daniela Herrera, Enrique A Castellon, Hector R Contreras
      Pages: 294 - 299
      Abstract: Octavio Orellana-Serradell, Daniela Herrera, Enrique A Castellon, Hector R Contreras
      Asian Journal of Andrology 2018 20(3):294-299
      It has been reported that one of the factors that promotes tumoral progression is the abnormal activation of the epithelial–mesenchymal transition program. This process is associated with tumoral cells acquiring invasive and malignant properties and has the transcription factor zinc finger E-box-binding homeobox 1 (ZEB1) as one of its main activators. However, the role of ZEB1 in promoting malignancy in prostate cancer (PCa) is still unclear. Here, we report that ZEB1 expression correlates with Gleason score in PCa samples and that expression of ZEB1 regulates epithelial–mesenchymal transition and malignant characteristics in PCa cell lines. The results showed that ZEB1 expression is higher in samples of higher malignancy and that overexpression of ZEB1 was able to induce epithelial–mesenchymal transition by upregulating the mesenchymal marker Vimentin and downregulating the epithelial marker E-Cadherin. On the contrary, ZEB1 silencing repressed Vimentin expression and upregulated E-Cadherin. ZEB1 expression conferred enhanced motility and invasiveness and a higher colony formation capacity to 22Rv1 cells whereas DU145 cells with ZEB1 silencing showed a decrease in those same properties. The results showed that ZEB1 could be a key promoter of tumoral progression toward advanced stages of PCa.
      Citation: Asian Journal of Andrology 2018 20(3):294-299
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_61_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • ASIC1a contributes to the symptom of pain in a rat model of chronic
           prostatitis

    • Authors: Song Fan, Zong-Yao Hao, Li Zhang, Jun Zhou, Yi-Fei Zhang, Shen Tai, Xian-Sheng Zhang, Chao-Zhao Liang
      Pages: 300 - 305
      Abstract: Song Fan, Zong-Yao Hao, Li Zhang, Jun Zhou, Yi-Fei Zhang, Shen Tai, Xian-Sheng Zhang, Chao-Zhao Liang
      Asian Journal of Andrology 2018 20(3):300-305
      This study aims to validate our hypothesis that acid-sensing ion channels (ASICs) may contribute to the symptom of pain in patients with chronic prostatitis (CP). We first established a CP rat model, then isolated the L5-S2 spinal dorsal horn neurons for further studies. ASIC1a was knocked down and its effects on the expression of neurogenic inflammation-related factors in the dorsal horn neurons of rat spinal cord were evaluated. The effect of ASIC1a on the Ca2+ ion concentration in the dorsal horn neurons of rat spinal cord was measured by the intracellular calcium ([Ca2+]i) intensity. The effect of ASIC1a on the p38/mitogen-activated protein kinase (MAPK) signaling pathway was also determined. ASIC1a was significantly upregulated in the CP rat model as compared with control rats. Acid-induced ASIC1a expression increased [Ca2+]i intensity in the dorsal horn neurons of rat spinal cord. ASIC1a also increased the levels of neurogenic inflammation-related factors and p-p38 expression in the acid-treated dorsal horn neurons. Notably, ASIC1a knockdown significantly decreased the expression of pro-inflammatory cytokines. Furthermore, the levels of p-p38 and pro-inflammatory cytokines in acid-treated dorsal horn neurons were significantly decreased in the presence of PcTx-1, BAPTA-AM, or SB203580. Our results showed that ASIC1a may contribute to the symptom of pain in patients with CP, at least partially, by regulating the p38/MAPK signaling pathway.
      Citation: Asian Journal of Andrology 2018 20(3):300-305
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_55_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Microdissection testicular extraction for a patient with transverse
           testicular ectopia and testicular fusion

    • Authors: Chen Chen, Yi-Chun Wang, Ya-Min Wang, Chao Qin, Ning-Hong Song
      Pages: 306 - 307
      Abstract: Chen Chen, Yi-Chun Wang, Ya-Min Wang, Chao Qin, Ning-Hong Song
      Asian Journal of Andrology 2018 20(3):306-307

      Citation: Asian Journal of Andrology 2018 20(3):306-307
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_33_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • A rare polypyrimidine tract mutation in the androgen receptor gene results
           in complete androgen insensitivity syndrome

    • Authors: Shi-Min Yuan, Huan Huang, Chao-Feng Tu, Juan Du, Da-Bao Xu, Ge Lin, Guang-Xiu Lu, Yue-Qiu Tan
      Pages: 308 - 310
      Abstract: Shi-Min Yuan, Huan Huang, Chao-Feng Tu, Juan Du, Da-Bao Xu, Ge Lin, Guang-Xiu Lu, Yue-Qiu Tan
      Asian Journal of Andrology 2018 20(3):308-310

      Citation: Asian Journal of Andrology 2018 20(3):308-310
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_32_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Redo surgery for failed hypospadias treatment using a novel single-stage
           repair

    • Authors: Min Wu, Shu-Zhu Chen, Wei-Jing Ye, Yi-Dong Liu
      Pages: 311 - 312
      Abstract: Min Wu, Shu-Zhu Chen, Wei-Jing Ye, Yi-Dong Liu
      Asian Journal of Andrology 2018 20(3):311-312

      Citation: Asian Journal of Andrology 2018 20(3):311-312
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_22_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • MRI feature analysis of uncommon prostatic malignant tumors

    • Authors: Zhao-Yan Feng, Xiang-De Min, Liang Wang, Ba-Sen Li, Zan Ke, Pei-Pei Zhang, Zhen Kang
      Pages: 313 - 315
      Abstract: Zhao-Yan Feng, Xiang-De Min, Liang Wang, Ba-Sen Li, Zan Ke, Pei-Pei Zhang, Zhen Kang
      Asian Journal of Andrology 2018 20(3):313-315

      Citation: Asian Journal of Andrology 2018 20(3):313-315
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_12_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Zinner's syndrome: clinical features and imaging diagnosis

    • Authors: Xiao-Song Jiang, Huan-Jun Wang, Jin-Hua Lin, Yan Guo, Can-Hui Sun, Ling Lin, Jian Guan
      Pages: 316 - 317
      Abstract: Xiao-Song Jiang, Huan-Jun Wang, Jin-Hua Lin, Yan Guo, Can-Hui Sun, Ling Lin, Jian Guan
      Asian Journal of Andrology 2018 20(3):316-317

      Citation: Asian Journal of Andrology 2018 20(3):316-317
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_21_17
      Issue No: Vol. 20, No. 3 (2018)
       
  • Commentary on “Altered PIWI-LIKE 1 and PIWI-LIKE 2 mRNA expression
           in ejaculated spermatozoa of men with impaired sperm
           characteristics”

    • Authors: De-Yi Liu
      Pages: 318 - 318
      Abstract: De-Yi Liu
      Asian Journal of Andrology 2018 20(3):318-318

      Citation: Asian Journal of Andrology 2018 20(3):318-318
      PubDate: Thu,26 Apr 2018
      DOI: 10.4103/aja.aja_67_17
      Issue No: Vol. 20, No. 3 (2018)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.162.239.233
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-